Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Combination of EZH2 inhibitor and STING agonist in melanoma cell lines

ABSTRACT: In order to better understand the effects of combination treatment with EZH2 inhibitor and STING agonist in human melanoma cells, RNA sequencing was performed to explore transcriptome alteration.

ORGANISM(S): Homo sapiens

PROVIDER: GSE171538 | GEO | 2021/10/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Combination of EZH2 inhibitor and STING agonist in melanoma cell lines

Project description:Combination of EZH2 inhibitor and STING agonist in melanoma cell lines

| PRJNA719921 | ENA

STING agonist alters the transcriptional profiles of HSPCs in melanoma-bearing mouse model

Project description:In order to better understand the effects of STING agonist diABZI on HSPCs, the LSKs and GMPs were sorted from mice BM and subjected to RNA sequencing to explore the transcriptome alteration after diABZI treatment.

2023-08-08 | GSE192927 | GEO

Transcriptome-wide identification of STING agonist programed B cells

Project description:We employed RNA-seq to study the transcriptomic change in B lymphocytes in response to STING agonist. Transcriptomic analysis of wild type and TMEM173–/– B cells stimulated with STING agonist revealed that the inflammatory response pathway enriched in 3'3'-cGAMP treated WT B cells but lacking in Tmem173-/-B cells comprised of a cluster containing inhibitory regulators, provoking STING signal to evade immune surveillance by inducing an immunosuppressive B cell population.

2022-08-10 | GSE199343 | GEO

DMXAA (STING agonist) efficacy on tumor microenvironment after CAR-T therapy

Project description:This study is designed to uncover the mechanism by which STING agonist (DMXAA) changes the tumor microenivorment of mammary tumor to support Th/Tc17 CAR-T cells treatment.

2020-11-25 | GSE162073 | GEO

NanoString immune gene expression analysis of PARP inhibitor and STING agonist treated mouse breast tumors

Project description:This study aimed to assess changes in immune gene expression and immune-related pathways in mouse tumors from syngeneic mice treated with combined PARP inhibitor and STING agonist therapy. The objective was to identify differentially expressed genes related to immune oncology in response to the combination treatment as compared to single treatments, in order to gain mechanistic insight into the enhanced anti-tumor efficacy of the combination treatment.

2022-05-29 | GSE204858 | GEO

Transcriptome-wide identification of STING agonist programed B cells

Project description:Transcriptome-wide identification of STING agonist programed B cells

| PRJNA819428 | ENA

STING agonist alters the transcriptional profiles of HSPCs in melanoma-bearing mouse model

Project description:STING agonist alters the transcriptional profiles of HSPCs in melanoma-bearing mouse model

| PRJNA793834 | ENA

Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100 [II]

Project description:Two murine melanoma models (B16 and BPR) were treated with PBS or STING agonist ADU-S100 in vivo. Dose 1 was administered intratumorally on day 10, and a second dose was given on day 14. Tumors were collected 6 hours after the second dose and RNA was isolated. RNA was run on the Nanostring mouse PanCancer Immune Profiling Panel.

2023-12-09 | GSE249295 | GEO

Gene expression profiles of murine melanoma after treatment with STING agonist ADU-S100 [I]

Project description:Gene expression profiles of murine melanoma after treatment with STING agonist ADU-S100 [I]

| PRJNA1048459 | ENA

DMXAA (STING agonist) efficacy on tumor microenvironment after CAR-T therapy

Project description:DMXAA (STING agonist) efficacy on tumor microenvironment after CAR-T therapy

| PRJNA680502 | ENA